Literature DB >> 10367591

Role of A2A receptor in the modulation of myocardial reperfusion damage.

A Cargnoni1, C Ceconi, A Boraso, P Bernocchi, A Monopoli, S Curello, R Ferrari.   

Abstract

Adenosine protects myocardium from ischemia and reperfusion damage; however, the mechanism of action is still under discussion. We investigated whether (a) adenosine protects isolated crystalloid-perfused rabbit heart from ischemia/ reperfusion injury; (b) this action is receptor mediated and what receptor subtypes are involved, and (c) this action is dependent on an enhanced nitric oxide production. Our results showed a cardioprotective effect of adenosine (10(-4) M), of nonselective adenosine-receptor agonist 5'-N-ethyl-carboxamidoadenosine (NECA; 5 x 10(-6) M), and of A2A agonists CGS 21680 (10(-8) and 10(-6) M), 2-hexynylNECA (10(-7) M). On the contrary, A1 agonist CCPA (10(-8) and 10(-6) M) does not provide any protection. The effect has been achieved in terms of significant reduction in contracture development during reperfusion [diastolic pressure was 46.8 +/- 7.1 mm Hg (p < 0.01); 46.1 +/- 7.8 mm Hg (p < 0.01); 46.9 +/- 5.5 mm Hg (p < 0.01); and 59.3 +/- 6.7 mm Hg (p < 0.05) with 10(-4) M adenosine, 5 x 10(-6) M NECA, 10(-6) M CGS 21680, and 10(-7) M 2-hexynylNECA, respectively, versus 77.6 +/- 5.0 mm Hg in control]; reduced creatine phosphokinase release (13.5 +/- 1.6, 22.2 +/- 7.9, 14.2 +/- 3.3, and 14.1 +/- 4.5 U/gww in treated hearts vs. 34.6 +/- 7.2 U/gww in controls; p < 0.05); improved energy metabolism [adenosine triphosphate (ATP) content is 9.9 +/- 0.5, 10.4 +/- 0.6, 9.8 +/- 0.5, and 10.5 +/- 0.5 micromol/gdw in treated hearts vs. 7.6 +/- 0.2 micromol/gdw; p < 0.05]. Moreover, our data indirectly show a functional presence of A2A receptors on cardiomyocytes as the protection is A2A mediated and exerted only during reperfusion, although in the absence of blood and coronary flow changes. These activities appear independent of nitric oxide pathways, as adenosine and 2-hexynylNECA effects are not affected by the presence of a nitric oxide-synthase inhibitor (10(-4) M L-NNA).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10367591     DOI: 10.1097/00005344-199906000-00008

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

Review 1.  Adenosine signaling and the regulation of chronic lung disease.

Authors:  Yang Zhou; Daniel J Schneider; Michael R Blackburn
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

Review 2.  Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning.

Authors:  Péter Ferdinandy; Richard Schulz
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

3.  Enhanced A2A adenosine receptor-mediated increase in coronary flow in type I diabetic mice.

Authors:  Hicham Labazi; Bunyen Teng; Zhichao Zhou; S Jamal Mustafa
Journal:  J Mol Cell Cardiol       Date:  2015-12-02       Impact factor: 5.000

4.  Characterization of ERK1/2 signalling pathways induced by adenosine receptor subtypes in newborn rat cardiomyocytes.

Authors:  Renée Germack; John M Dickenson
Journal:  Br J Pharmacol       Date:  2004-01       Impact factor: 8.739

5.  Reduction in myocardial infarct size at 48 hours after brief intravenous infusion of ATL-146e, a highly selective adenosine A2A receptor agonist.

Authors:  Rajan A G Patel; David K Glover; Alexis Broisat; Hasan K Kabul; Mirta Ruiz; N Craig Goodman; Christopher M Kramer; Denis J Meerdink; Joel Linden; George A Beller
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-06-05       Impact factor: 4.733

6.  Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation.

Authors:  Tyler H Rork; Kori L Wallace; Dylan P Kennedy; Melissa A Marshall; Amy R Lankford; Joel Linden
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-29       Impact factor: 4.733

7.  Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade.

Authors:  Rodrigo A Cunha
Journal:  Purinergic Signal       Date:  2005-03-17       Impact factor: 3.765

8.  Phenotyping of Mice with Heart Specific Overexpression of A2A-Adenosine Receptors: Evidence for Cardioprotective Effects of A2A-Adenosine Receptors.

Authors:  Peter Boknik; Katharina Drzewiecki; John Eskandar; Ulrich Gergs; Stephanie Grote-Wessels; Larissa Fabritz; Paulus Kirchhof; Frank U Müller; Frank Stümpel; Wilhelm Schmitz; Norbert Zimmermann; Uwe Kirchhefer; Joachim Neumann
Journal:  Front Pharmacol       Date:  2018-01-22       Impact factor: 5.810

9.  Evidence for Arrhythmogenic Effects of A2A-Adenosine Receptors.

Authors:  Peter Boknik; Katharina Drzewiecki; John Eskandar; Ulrich Gergs; Britt Hofmann; Hendrik Treede; Stephanie Grote-Wessels; Larissa Fabritz; Paulus Kirchhof; Lisa Fortmüller; Frank Ulrich Müller; Wilhelm Schmitz; Norbert Zimmermann; Uwe Kirchhefer; Joachim Neumann
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

Review 10.  Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.

Authors:  Chrisna Matthee; Gisella Terre'Blanche; Lesetja J Legoabe; Helena D Janse van Rensburg
Journal:  Mol Divers       Date:  2021-06-27       Impact factor: 3.364

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.